Shares of HENLIUS (02696.HK) surged 10.81% during the intraday trading session on Friday, following news of a licensing deal with India-based pharmaceutical company Dr. Reddy's Laboratories (REDY.NS) for its myeloma drug HLX15.
Under the agreement, HENLIUS will grant Dr. Reddy's the license to develop, manufacture, and commercialize HLX15 in the United States, United Kingdom, Switzerland, and 42 other European countries. Dr. Reddy's will pay an upfront payment of $33 million, milestone payments of up to $98.6 million, and royalties of up to 8% of annual net sales to HENLIUS.
HLX15 is a biopharmaceutical product used for the treatment of multiple myeloma, a type of blood cancer. The deal represents a significant step in HENLIUS's expansion into overseas markets and reflects the growing demand for innovative cancer treatments globally.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。